Wellington Management Group LLP reduced its position in shares of Evotec SE (NASDAQ:EVO - Free Report) by 12.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,299,905 shares of the company's stock after selling 334,529 shares during the quarter. Wellington Management Group LLP owned 0.65% of Evotec worth $9,568,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in shares of Evotec in the fourth quarter worth $27,000. CSS LLC IL purchased a new stake in shares of Evotec during the fourth quarter worth $50,000. Bank of America Corp DE raised its holdings in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec during the fourth quarter worth $166,000. Finally, DCF Advisers LLC raised its holdings in shares of Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after acquiring an additional 12,816 shares in the last quarter. 5.81% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on EVO shares. Royal Bank of Canada reiterated an "outperform" rating on shares of Evotec in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $5.93.
View Our Latest Analysis on Evotec
Evotec Price Performance
NASDAQ:EVO traded up $0.04 during trading hours on Friday, reaching $4.05. The company's stock had a trading volume of 35,221 shares, compared to its average volume of 132,619. Evotec SE has a one year low of $2.84 and a one year high of $5.64. The business's 50-day moving average is $3.85 and its 200-day moving average is $4.13. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.
About Evotec
(
Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
